THE Dr Antoni Esteve Foundation granted his Research Prize 2024 has Iker Ausejo And Martha Alonsoresearchers from High and the Clinic of the University of Navarra. His research team published in 2023 an article in the magazine Cancer cellwhere they confirmed a possible “therapeutic target” for childhood cancer more aggressive. Marthe Estèvepatron of the Foundation, was responsible for presenting the prize to Iker Ausejofirst author of the award-winning article.
The delivery event brought together President of the Royal Academy of Pharmacy of Catalonia, Joan Permanyerand the Deputy Director General of Health Research and Innovation of the Generalitat of Catalonia, Montserrat Llavayolwhich highlighted the work of the Foundation in promoting scientific research. “Through the dedication with which you speak about your research, you convey to us this imperative need to fight to find funds for research,” he commented about the winners.
Pol Moraleshead of communications for the Foundation, stressed that the award-winning research “represents an important contribution to therapy against a type of childhood cancer characterized by its particular aggressiveness. It is a pride that the Dr Antoni Esteve Foundation Research Award this year comes across a work which perfectly illustrates the mission and values of this institution in favor of innovation and the quality in the investigation.”
Jaume Piulatsmember of the jury Dr Antoni Esteve Foundation Research Prize 2024explained that “Iker Ausejo and the team led by Martha Alonso showed that TIM-3 may be a target for treatment diffuse intrinsic pontine glioma (DIPG)an aggressive brainstem tumor and the leading cause of cancer-related deaths in children. “The decision was unanimous among the jurors, among whom were Ralph Jockersof the Cochin Institute from Paris, and Christian Beausejourof the University of Montrealaccording to a press release from the Foundation.
Due to the location of the tumor, therapeutic options for the GPID are limited, it is therefore “essential to study effective treatments”. “In recent years, the immunotherapy It has proven to be an alternative for many types of cancer. However, due to the unique tumor microenvironment of GPID“conventional inhibitors have not been effective in these pediatric patients,” explained Iker Ausejo.
This research, integrated into the Clinic of the Cancer Center of the University of Navarrashows that the inhibition of TIM-3 promotes a pro-inflammatory tumor microenvironment that “promotes a potent anti-tumor immune response.” “As a result, the long term survival experimental models. SO, TIM-3 “is presented as a therapeutic target that can guide the development of clinical trials for these patients,” he added. Martha Alonsoco-director of the Program Solid tumors of the High and studio director.
He Dr Antoni Esteve Foundation Research Award this year rewarded the best research in pharmacology published in the last three years by an author of Spanish nationality in an international scientific journal. The prize is endowed with 25,000 euros.
